Related Experiment Video
Updated: Jan 20, 2026

Studying Triple Negative Breast Cancer Using Orthotopic Breast Cancer Model
Published on: March 20, 2020
Therapeutic genome editing of triple-negative breast tumors using a noncationic and deformable nanolipogel
Peng Guo1,2,3, Jiang Yang1,2,3, Jing Huang1,2,3
1Vascular Biology Program, Boston Children's Hospital, Boston, MA 02115.
Abstract:
Triple-negative breast cancer (TNBC), which has the highest mortality rate of all breast cancer, is in urgent need of a therapeutic that hinders the spread and growth of cancer cells. CRISPR genome editing holds the promise of a potential cure for many genetic diseases, including TNBC; however, its clinical translation is being challenged by the lack of safe and effective nonviral delivery systems for in vivo therapeutic genome editing. Here we report the synthesis and application of a noncationic, deformable, and tumor-targeted nanolipogel system (tNLG) for CRISPR genome editing in TNBC tumors. We have demonstrated that tNLGs mediate a potent CRISPR knockout of Lipocalin 2 (Lcn2), a known breast cancer oncogene, in human TNBC cells in vitro and in vivo. The loss of Lcn2 significantly inhibits the migration and the mesenchymal phenotype of human TNBC cells and subsequently attenuates TNBC aggressiveness. In an orthotopic TNBC model, we have shown that systemically administered tNLGs mediated >81% CRISPR knockout of Lcn2 in TNBC tumor tissues, resulting in significant tumor growth suppression (>77%). Our proof-of-principle results provide experimental evidence that tNLGs can be used as a safe, precise, and effective delivery approach for in vivo CRISPR genome editing in TNBC.
Insights
A novel nanolipogel system (tNLG) effectively delivers CRISPR genome editing to triple-negative breast cancer (TNBC) tumors. This approach targets the Lcn2 oncogene, significantly inhibiting TNBC cell migration and tumor growth.
Area of Science:
- Biomedical Engineering
- Oncology
- Gene Therapy
Background:
- Triple-negative breast cancer (TNBC) presents a high mortality rate and lacks effective therapeutics.
- CRISPR genome editing offers therapeutic potential for TNBC, but safe and effective in vivo delivery remains a challenge.
- Nonviral delivery systems are crucial for clinical translation of CRISPR-based therapies.
Purpose of the Study:
- To develop and evaluate a novel noncationic, deformable, and tumor-targeted nanolipogel system (tNLG) for CRISPR genome editing in TNBC.
- To assess the efficacy of tNLGs in delivering CRISPR to knockout the Lcn2 oncogene in TNBC cells.
- To determine the therapeutic impact of Lcn2 inhibition on TNBC progression and tumor growth in vivo.
Main Methods:
- Synthesis and characterization of the tumor-targeted nanolipogel (tNLG) system.
- In vitro and in vivo CRISPR-Cas9 genome editing targeting Lipocalin 2 (Lcn2) in human TNBC cells.
- Evaluation of Lcn2 knockout effects on TNBC cell migration and mesenchymal phenotype.
- Assessment of tNLG delivery, Lcn2 knockout efficiency, and tumor growth suppression in an orthotopic TNBC mouse model.
Main Results:
- The tNLG system was successfully synthesized and demonstrated deformability and tumor-targeting capabilities.
- tNLGs mediated potent CRISPR knockout of Lcn2 in TNBC cells both in vitro and in vivo.
- Loss of Lcn2 significantly inhibited TNBC cell migration and mesenchymal characteristics.
- Systemic administration of tNLGs achieved >81% Lcn2 knockout in TNBC tumors, leading to >77% tumor growth suppression.
Conclusions:
- The developed tNLG system serves as a safe, precise, and effective nonviral delivery vehicle for CRISPR genome editing in TNBC.
- Targeting the Lcn2 oncogene via CRISPR/tNLG delivery attenuates TNBC aggressiveness and suppresses tumor growth.
- This study provides a promising proof-of-concept for tNLG-mediated in vivo gene editing as a therapeutic strategy for TNBC.
Related Concept Videos
CRISPR/Cas9 Genome Editing
RNA Editing
Plastic Deformations
Plastic Deformations
Genomics
Temperature Dependent Deformation

